eftilagimod alfa

Phase 3Biologic

IImmutep S.A.S.

eftilagimod alfa is one of 96 biologic programs targeting Breast Carcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Breast CarcinomaActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Breast CancerActive, not recruiting

Breast CarcinomaPhase 1

Active, not recruiting

Non-Small Cell Lung CancerPhase 3

Active, not recruiting

Breast CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

eftilagimod alfa

IImmutep S.A.S.

Phase 3

2 2

Nolvadex

SSan Diego Pacific Oncology & Hematology Associates

Preclinical

78 3

Cymbalta

Alnylam Pharmaceuticals

Preclinical

3 4

Lupron

EEastern Cooperative Oncology Group

Preclinical

5 5

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 6

Zinecard

CChildren's Oncology Group

Preclinical

2 7

Spravato

WWim Janssens

Preclinical

2 8

Chirocaine

PPurdue Pharma LP

Preclinical

1 9

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 10

Nubain

AAultman Health Foundation

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2/3Active, not recruiting

Breast Cancer

NCT05747794

Q3 2028

Phase 2Not yet recruiting

Breast Cancer

NCT07102940

Q3 2029

Phase 3Active, not recruiting

Non-Small Cell Lung Cancer

NCT06726265

Clinical

Trials by Indication[1]

Recurrent or Metastatic2 trials

Combination Study With Eftilagimod Alpha (a Soluble LAG-3 Fusion Protein) and Pembrolizumab in Patients With Recurrent or Metastatic HNSCC

Completed·IImmutep S.A.S.·Phase 2·NCT04811027·171 enrolled

Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC

Completed·IImmutep S.A.S.·Phase 2·NCT03625323·187 enrolled

Breast Cancer2 trials

Study in Metastatic Breast Cancer Patients Receiving Eftilagimod Alpha or Placebo in Combination with Paclitaxel Chemotherapy

Active, not recruiting·IImmutep S.A.S.·Phase 2/3·NCT05747794·849 enrolled

Efti in Patients With Hormone Receptor Positive/HER2-neg Breast Cancer

Not yet recruiting·GGeorge Washington University·Phase 2·NCT07102940·50 enrolled

Breast Carcinoma1 trial

A Study in Hormone Receptor-positive Metastatic Breast Carcinoma Patients to Test a New Schedule of Efti (IMP321, Eftilagimod Alpha) as Adjunctive to a Weekly Treatment Regimen of Paclitaxel

Withdrawn·IImmutep S.A.S.·Phase 1·NCT04252768

Non-Small Cell Lung Cancer1 trial

Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)

Active, not recruiting·IImmutep S.A.S.·Phase 3·NCT06726265·756 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for eftilagimod alfa. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — eftilagimod alfa compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for eftilagimod alfa. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Immutep S.A.S. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: IImmutep S.A.S.

eftilagimod alfa

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q3 2028

Q3 2029

Trials by Indication[1]

Recurrent or Metastatic2 trials

Breast Cancer2 trials

Breast Carcinoma1 trial

Non-Small Cell Lung Cancer1 trial

References

Drug Info

Quick Facts

Related News